Analysis of Polymorphism of Androgen Receptor in Cases of Androgenetic Alopecia

    January 2011 in “ The Chinese Journal of Dermatovenereology ”
    Wang Wei
    TLDR Shorter GGN repeats in the androgen receptor gene are linked to androgenetic alopecia.
    The study investigated the association between androgen receptor polymorphisms and androgenetic alopecia in 43 affected males and 27 controls. It found that the length of GGN repeats in the androgen receptor gene was correlated with androgenetic alopecia, with repeats of ≤23 being highly associated with the condition. However, no polymorphisms were found in the SNPs rs9332969 and rs9332970 among the Chinese participants, which differed significantly from the 50% occurrence reported in GENBANK of NCBI.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 1000+ results

      community A Technical Question About Pyrilutamide

      in Research/Science  5 upvotes 2 years ago
      Pyrilutamide is believed to be more effective than RU58841 and 1 mg finasteride in treating hair loss, with no systemic hormonal effects and the potential to block more than 31% of scalp DHT. It may also antagonize scalp testosterone due to its action as an androgen receptor antagonist.

      community Fluridil degrades the androgen receptor.

      in Research/Science  12 upvotes 6 months ago
      Fluridil degrades androgen receptors, which are prevalent in the scalp and other tissues. People with androgenetic alopecia (AGA) may have higher expression of these receptors and 5AR activity in affected scalp areas.

      community Chat is this real? Compound called clascoterone

      in Research/Science  584 upvotes 2 weeks ago
      Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  135 upvotes 1 year ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

    Related Research

    5 / 5 results